Allergy Therapeutics: Earnings ABOVE expectations, COVID-19 Diagnostic Facility

15th July 2020 | Allergy Therapeutics plc

Strong 2020 performance despite COVID-19 challenge

  • Earnings above market expectations
  • Net revenue of £78.2million representing 6% annual growth
  • Strong cash balance of £37.0 million
  • Phase I Peanut program fully funded from existing resources
  • Licencing deal signed for new oral treatment, ImmunoBON
  • COVID-19 diagnostic facility approved by Spanish authorities

Allergy Therapeutics Investors Video

CEO Manuel Llobet on Five Minute pitch TV updating investors on the progress of their allergy vaccines

Click here to view Allergy Therapeutics investor video